TY  - JOUR
AU  - Beyer, GJ
AU  - Čomor, Jožef J.
AU  - Dakovic, M
AU  - Soloviev, D
AU  - Tamburella, C
AU  - Hagebo, E
AU  - Allan, B
AU  - Dmitriev, SN
AU  - Zaitseva, NG
AU  - Starodub, GY
AU  - Molokanova, LG
AU  - Vranješ, Sanja
AU  - Miederer, M
AU  - ISOLDE Collaboration
PY  - 2002
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2520
AB  - The partial alpha emitting lanthanide isotope Tb-149 seems to have a great potential in systemic radioimmuno therapy (RIT), especially when single cells in transit or circulation are targeted. The isotope Tb-149 has a half life of 4.118h and decays by alpha emission (3.97MeV, 17%) EC-process (76%) and beta(+)-emission (7%). In this paper. we analyze the possible production routes: light- and heavy ion induced nuclear reactions and p-induced spallation. The excitation functions for light- and heavy ion induced reactions have been calculated using the ALICE91 code. The direct nuclear reaction Gd-152 (p, 4n) Tb-149 was found to be the most promising production path. Alternatively, the indirect reaction Nd-142 (C-12 5n) Dy-149 -- GT Tb-149 seems to be much more suitable compared to the reaction on the mono-isotopic target element Pr-141 (C-12, 4n) Tb-149. In this case, both, the production yield of Tb-149 and the radionuclidic purity are considerably lower, compared to the (p, 4n)-reaction. In preliminary experiments we produced Tb-149 via the indirect reaction Nd (C-12, 5n) Dy-149 -- GT Tb-149 (108 MeV C-12(+6) ions and 1 particle-muA) at the U-200 heavy ion cyclotron at the FLNR of the JINR Dubna. From a 1.25 It irradiation of a 12 mg/cm(2) (Nd2O3)-Nd-nat target, we obtained 2.7 MBq of Tb-149 (70 muCi) at 20 min EOB. This allows the conclusion, that a dedicated cyclotron equipped with a modem ECR-ion source, providing high ion currents would allow the continuous production of batches of the order of 10-20 GBq of Tb-149 for routine RI-therapy. The lower cross section of the spallation process can be compensated by using very thick targets. On-line mass separation technique provides high purity isotopically clean Tb-149 preparations, independently on the production route chosen. At the ISOLDE facility at CERN, we prepared batches of up to 500 MBq Tb-149 by combining on-line mass separation process followed by a cation exchange chromatography process using alpha-HIBA as eluent. The obtained Tb-149 preparations showed excellent behavior in labeling of chelated monoclonal antibodies.
T2  - Radiochimica Acta
T1  - Production routes of the alpha emitting Tb-149 for medical application
VL  - 90
IS  - 5
SP  - 247
EP  - 252
DO  - 10.1524/ract.2002.90.5_2002.247
ER  - 

@article{
author = "Beyer, GJ and Čomor, Jožef J. and Dakovic, M and Soloviev, D and Tamburella, C and Hagebo, E and Allan, B and Dmitriev, SN and Zaitseva, NG and Starodub, GY and Molokanova, LG and Vranješ, Sanja and Miederer, M and ISOLDE Collaboration",
year = "2002",
abstract = "The partial alpha emitting lanthanide isotope Tb-149 seems to have a great potential in systemic radioimmuno therapy (RIT), especially when single cells in transit or circulation are targeted. The isotope Tb-149 has a half life of 4.118h and decays by alpha emission (3.97MeV, 17%) EC-process (76%) and beta(+)-emission (7%). In this paper. we analyze the possible production routes: light- and heavy ion induced nuclear reactions and p-induced spallation. The excitation functions for light- and heavy ion induced reactions have been calculated using the ALICE91 code. The direct nuclear reaction Gd-152 (p, 4n) Tb-149 was found to be the most promising production path. Alternatively, the indirect reaction Nd-142 (C-12 5n) Dy-149 -- GT Tb-149 seems to be much more suitable compared to the reaction on the mono-isotopic target element Pr-141 (C-12, 4n) Tb-149. In this case, both, the production yield of Tb-149 and the radionuclidic purity are considerably lower, compared to the (p, 4n)-reaction. In preliminary experiments we produced Tb-149 via the indirect reaction Nd (C-12, 5n) Dy-149 -- GT Tb-149 (108 MeV C-12(+6) ions and 1 particle-muA) at the U-200 heavy ion cyclotron at the FLNR of the JINR Dubna. From a 1.25 It irradiation of a 12 mg/cm(2) (Nd2O3)-Nd-nat target, we obtained 2.7 MBq of Tb-149 (70 muCi) at 20 min EOB. This allows the conclusion, that a dedicated cyclotron equipped with a modem ECR-ion source, providing high ion currents would allow the continuous production of batches of the order of 10-20 GBq of Tb-149 for routine RI-therapy. The lower cross section of the spallation process can be compensated by using very thick targets. On-line mass separation technique provides high purity isotopically clean Tb-149 preparations, independently on the production route chosen. At the ISOLDE facility at CERN, we prepared batches of up to 500 MBq Tb-149 by combining on-line mass separation process followed by a cation exchange chromatography process using alpha-HIBA as eluent. The obtained Tb-149 preparations showed excellent behavior in labeling of chelated monoclonal antibodies.",
journal = "Radiochimica Acta",
title = "Production routes of the alpha emitting Tb-149 for medical application",
volume = "90",
number = "5",
pages = "247-252",
doi = "10.1524/ract.2002.90.5_2002.247"
}

Beyer, G., Čomor, J. J., Dakovic, M., Soloviev, D., Tamburella, C., Hagebo, E., Allan, B., Dmitriev, S., Zaitseva, N., Starodub, G., Molokanova, L., Vranješ, S., Miederer, M.,& ISOLDE Collaboration. (2002). Production routes of the alpha emitting Tb-149 for medical application. in Radiochimica Acta, 90(5), 247-252.
https://doi.org/10.1524/ract.2002.90.5_2002.247

Beyer G, Čomor JJ, Dakovic M, Soloviev D, Tamburella C, Hagebo E, Allan B, Dmitriev S, Zaitseva N, Starodub G, Molokanova L, Vranješ S, Miederer M, ISOLDE Collaboration. Production routes of the alpha emitting Tb-149 for medical application. in Radiochimica Acta. 2002;90(5):247-252.
doi:10.1524/ract.2002.90.5_2002.247 .

Beyer, GJ, Čomor, Jožef J., Dakovic, M, Soloviev, D, Tamburella, C, Hagebo, E, Allan, B, Dmitriev, SN, Zaitseva, NG, Starodub, GY, Molokanova, LG, Vranješ, Sanja, Miederer, M, ISOLDE Collaboration, "Production routes of the alpha emitting Tb-149 for medical application" in Radiochimica Acta, 90, no. 5 (2002):247-252,
https://doi.org/10.1524/ract.2002.90.5_2002.247 . .